AGY Therapeutics was founded in 1998, when Dr. Karoly Nikolich approached venture capitalist Robert A. Swanson. AGY Therapeutics is establishing a strong proprietary position for a large number of novel pharmaceutical agents, diagnostics and technologies. In its short history, the company has built a proprietary technology platform for functional gene discovery and for delineating specific mechanistic pathways underlying central nervous system diseases. AGY Therapeutics' aggressive business strategy is designed to create shareholder value and to realize income from multiple revenue streams. AGY Therapeutics intends to forge pharmaceutical partnerships for the development and commercialization of novel markers for diagnosing and treating central nervous system diseases. AGY Therapeutics will also Out-license specific, well-characterized drug targets and innovative diagnostic opportunities, as well as Out-license and partner specific lead compounds for therapeutic development.